These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29660005)

  • 41. Automated Volumetric Analysis of Postoperative Magnetic Resonance Imaging Predicts Survival in Patients with Glioblastoma.
    Krivoshapkin AL; Sergeev GS; Gaytan AS; Kalneus LE; Kurbatov VP; Abdullaev OA; Salim N; Bulanov DV; Simonovich AE
    World Neurosurg; 2019 Jun; 126():e1510-e1517. PubMed ID: 30910753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study.
    Morisse MC; Etienne-Selloum N; Bello-Roufai D; Blonski M; Taillandier L; Lorgis V; Noël G; Ahle G; Durán-Peña A; Boone M; Chauffert B
    J Neurooncol; 2019 Sep; 144(2):419-426. PubMed ID: 31325146
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Survival after reoperation for recurrent glioblastoma.
    Woodroffe RW; Zanaty M; Soni N; Mott SL; Helland LC; Pasha A; Maley J; Dhungana N; Jones KA; Monga V; Greenlee JDW
    J Clin Neurosci; 2020 Mar; 73():118-124. PubMed ID: 31987636
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dynamics of FLAIR Volume Changes in Glioblastoma and Prediction of Survival.
    Grossman R; Shimony N; Shir D; Gonen T; Sitt R; Kimchi TJ; Harosh CB; Ram Z
    Ann Surg Oncol; 2017 Mar; 24(3):794-800. PubMed ID: 27766560
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prediction of survival with multi-scale radiomic analysis in glioblastoma patients.
    Chaddad A; Sabri S; Niazi T; Abdulkarim B
    Med Biol Eng Comput; 2018 Dec; 56(12):2287-2300. PubMed ID: 29915951
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.
    Kalpathy-Cramer J; Chandra V; Da X; Ou Y; Emblem KE; Muzikansky A; Cai X; Douw L; Evans JG; Dietrich J; Chi AS; Wen PY; Stufflebeam S; Rosen B; Duda DG; Jain RK; Batchelor TT; Gerstner ER
    J Neurooncol; 2017 Feb; 131(3):603-610. PubMed ID: 27853960
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of removed tumor volume and location on patient outcome in glioblastoma.
    Awad AW; Karsy M; Sanai N; Spetzler R; Zhang Y; Xu Y; Mahan MA
    J Neurooncol; 2017 Oct; 135(1):161-171. PubMed ID: 28685405
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma.
    da Fonseca CO; Simão M; Lins IR; Caetano RO; Futuro D; Quirico-Santos T
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):287-93. PubMed ID: 20401670
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.
    Molina D; Pérez-Beteta J; Martínez-González A; Sepúlveda JM; Peralta S; Gil-Gil MJ; Reynes G; Herrero A; De Las Peñas R; Luque R; Capellades J; Balaña C; Pérez-García VM
    PLoS One; 2016; 11(8):e0161484. PubMed ID: 27557121
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
    Galla N; Chiang G; Chakraborty S; Singh R; John Tsiouris A; Boockvar J; Kovanlikaya I
    Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
    Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
    J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Matulonis UA; Sill MW; Makker V; Mutch DG; Carlson JW; Darus CJ; Mannel RS; Bender DP; Crane EK; Aghajanian C
    Gynecol Oncol; 2019 Mar; 152(3):548-553. PubMed ID: 30587441
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
    Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
    Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study.
    Jayachandran Preetha C; Meredig H; Brugnara G; Mahmutoglu MA; Foltyn M; Isensee F; Kessler T; Pflüger I; Schell M; Neuberger U; Petersen J; Wick A; Heiland S; Debus J; Platten M; Idbaih A; Brandes AA; Winkler F; van den Bent MJ; Nabors B; Stupp R; Maier-Hein KH; Gorlia T; Tonn JC; Weller M; Wick W; Bendszus M; Vollmuth P
    Lancet Digit Health; 2021 Dec; 3(12):e784-e794. PubMed ID: 34688602
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
    Smith M; De Bono J; Sternberg C; Le Moulec S; Oudard S; De Giorgi U; Krainer M; Bergman A; Hoelzer W; De Wit R; Bögemann M; Saad F; Cruciani G; Thiery-Vuillemin A; Feyerabend S; Miller K; Houédé N; Hussain S; Lam E; Polikoff J; Stenzl A; Mainwaring P; Ramies D; Hessel C; Weitzman A; Fizazi K
    J Clin Oncol; 2016 Sep; 34(25):3005-13. PubMed ID: 27400947
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab.
    Ellingson BM; Cloughesy TF; Lai A; Nghiemphu PL; Mischel PS; Pope WB
    Neuro Oncol; 2011 Apr; 13(4):401-9. PubMed ID: 21324937
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.
    Leu K; Boxerman JL; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
    J Magn Reson Imaging; 2016 Nov; 44(5):1229-1237. PubMed ID: 26971534
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.
    Bag AK; Cezayirli PC; Davenport JJ; Gaddikeri S; Fathallah-Shaykh HM; Cantor A; Han XS; Nabors LB
    J Neurooncol; 2014 Nov; 120(2):361-70. PubMed ID: 25098699
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy.
    Hattingen E; Bähr O; Rieger J; Blasel S; Steinbach J; Pilatus U
    PLoS One; 2013; 8(3):e56439. PubMed ID: 23520454
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma.
    Phuphanich S; Raizer J; Chamberlain M; Canelos P; Narwal R; Hong S; Miday R; Nade M; Laubscher K
    J Neurooncol; 2017 Jan; 131(1):185-191. PubMed ID: 27844311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.